SCHEMBL6695094

SCHEMBL6695094

N#Cc1c(-c2ccccc2F)ccc(Br)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.40
ADORA2A P29274 2/20 0.40
ADORA2B P29275 2/20 0.38
ALDH1A1 P00352 6/20 0.37
KDM4E B2RXH2 4/20 0.37
HPGD P15428 4/20 0.37
GAA P10253 2/20 0.37
GLA P06280 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CUL4A Q13619 1/20 0.36
PTPRC P08575 1/20 0.34
PTPN1 P18031 1/20 0.34
HSD17B10 Q99714 3/20 0.34
MAPK1 P28482 1/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
DYRK1A Q13627 1/20 0.33
CHUK O15111 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2651898 0.81 ADORA1 (0.41) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL29967703 0.81 MAPK1 (0.46) ADORA1ADORA2AALDH1A1KDM4EHPGD
SCHEMBL2652913 0.81 MAPK1 (0.46) ADORA1ADORA2AALDH1A1KDM4EHPGD
SCHEMBL28609962 0.80 PTPRC (0.39) ALDH1A1KDM4ESMN1; SMN2PTPRCPTPN1
SCHEMBL2650101 0.79 ADORA1 (0.47) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL2569036 0.77 ADORA1 (0.46) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL6695099 0.77 ADORA1 (0.38) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL29450561 0.75 TRPV4 (0.37) ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2729265 0.75 TRPV4 (0.37) ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2652911 0.75 ADORA1 (0.39) ADORA1ADORA2AADORA2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040171633-A1 (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses MERCK SHARP & DOHME LTD. (GB) 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171633-A1 (1, 8) naphthyridines as gaba ligands, their pharmaceutical compositions and uses GABRA1, GABRA4, GABRA6 ADORA1 131/4885ADORA2A 111/4885ADORA2B 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.